Algert Global LLC Has $2.77 Million Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Algert Global LLC grew its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 192.6% during the 3rd quarter, HoldingsChannel reports. The firm owned 259,160 shares of the biopharmaceutical company’s stock after purchasing an additional 170,575 shares during the quarter. Algert Global LLC’s holdings in Amicus Therapeutics were worth $2,768,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Assenagon Asset Management S.A. acquired a new stake in Amicus Therapeutics during the 2nd quarter worth $8,386,000. M&G Plc increased its holdings in shares of Amicus Therapeutics by 12.4% in the second quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock worth $7,485,000 after acquiring an additional 82,728 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its position in shares of Amicus Therapeutics by 7.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock worth $1,183,000 after purchasing an additional 7,304 shares during the period. Fiera Capital Corp raised its position in shares of Amicus Therapeutics by 1.1% during the second quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock worth $52,382,000 after purchasing an additional 58,113 shares during the period. Finally, Mutual of America Capital Management LLC lifted its holdings in shares of Amicus Therapeutics by 24.2% during the 2nd quarter. Mutual of America Capital Management LLC now owns 250,293 shares of the biopharmaceutical company’s stock valued at $2,483,000 after purchasing an additional 48,802 shares in the last quarter.

Analysts Set New Price Targets

Several brokerages have commented on FOLD. Cantor Fitzgerald raised their target price on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 price objective on the stock. JPMorgan Chase & Co. upped their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Bank of America lifted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, October 17th. Finally, StockNews.com raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 16th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $17.63.

Insider Activity at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total transaction of $87,825.00. Following the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $10,382,718.34. This represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders sold 30,401 shares of company stock valued at $352,038. Insiders own 2.20% of the company’s stock.

Amicus Therapeutics Price Performance

Shares of NASDAQ FOLD opened at $9.87 on Wednesday. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. The business has a 50-day moving average of $10.80 and a 200-day moving average of $10.59. The stock has a market capitalization of $2.95 billion, a price-to-earnings ratio of -29.15 and a beta of 0.68. Amicus Therapeutics, Inc. has a fifty-two week low of $9.02 and a fifty-two week high of $14.57.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.